glp-1 aging and Longevity: A New Approach The multifaceted role of GLP-1
Description
A very recent narrative review by Espinosa De Ycaza et al
Three FDA-approved GLP-1 medications are eligible under the bridge program when used to reduce excess body weight and maintain weight reduction: Wegovy (semaglutide), available as a weekly injection or daily oral tablet, manufactured by Novo Nordisk Zepbound (tirzepatide), available in the KwikPen autoinjector format, manufactured by Eli Lilly Foundayo (orforglipron), the first non-peptide, small-molecule oral GLP-1 for weight loss, recently FDA-approved and manufactured by Eli Lilly Each of these medications works by mimicking the activity of glucagon-like peptide-1, a hormone that regulates appetite, fullness, and blood sugar
To generate this data set, we applied DART-Seq, a scRNA-Seq technique, to the study of human islets
"Sometimes I feel like Im cheating myself by doing this, and I know a lot of people who arent overweight like I am who are taking it
The value of a clinic-based approach is not just in the treatments offered
Kidney Int 98:769777
